IP38-21: Testosterone suppression and recovery in patients with advanced prostate cancer treated with relugolix: an interim analysis of the OPTYX study

Saturday, May 16, 2026 1:00 PM to 3:00 PM · 1 hr. 59 min. (America/New_York)
146A
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!